| 產(chǎn)品描述： | Trapidil is a coronary vasodilator agent. It was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease. |
| 靶點(diǎn)： |
PDGFR;PDE |
| 體內(nèi)研究： |
Trapidil is an antiplatelet drug with specific platelet-derived growth factor antagonism and antiproliferative effects in the rat and rabbit models after balloon angioplasty. Trapidil had a potent inhibitory effect on osteoclast formation and bone resorption induced by interleukin-1 in an animal model. No abnormal symptoms, such as changes in body weight, diarrhea, high fever, and convulsion, were observed after intraperitoneal injections of trapidil |
| 細(xì)胞實(shí)驗(yàn)： |
Cell viability was determined by Trypan blue dye exclusion test and LDH assay. Supernatants, collected from cells seeded in serum-free medium and exposed to the different mitogens and drugs tested, were centrifuged and LDH concentration determined. Supernatants obtained from sonicated cells were used as a positive control. Furthermore, to definitely exclude a cytotoxic effect of Trapidil on human MC, cells incubated for four days with and without the drug were challenged with fresh medium containing 10% FBS, and cell proliferation evaluated. (Only for Reference) |
| 參考文獻(xiàn)： |
1.Gesualdo L, et al. Kidney Int. 1994, 46(4):1002-9. 2.Kim SD, et al. Biochem Pharmacol. 2013, 86(6):782-90. 3.Maresta A, et al. Circulation. 1994, 90(6):2710-5. |
| 溶解性： |
Ethanol:39 mg/mL (190 mM) DMSO:39 mg/mL (190 mM) H2O:38 mg/mL (185.1 mM) |
| 保存條件： |
-20℃,避光 |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
4.872 ml |
24.359 ml |
48.719 ml |
| 5 mM |
0.974 ml |
4.872 ml |
9.744 ml |
| 10 mM |
0.487 ml |
2.436 ml |
4.872 ml |
| 50 mM |
0.097 ml |
0.487 ml |
0.974 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險(xiǎn)品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京